3.8 USD
-0.01 (-0.26%)
3.856 USD
+0.06 (+1.47%)
We assign a fundamental rating of 4 out of 10 to BDTX. BDTX was compared to 535 industry peers in the Biotechnology industry. While BDTX has a great health rating, its profitability is only average at the moment. BDTX is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BDTX had positive earnings in the past year.
BDTX had a positive operating cash flow in the past year.
In the past 5 years BDTX always reported negative net income.
In the past 5 years BDTX always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 8.43%, BDTX belongs to the best of the industry, outperforming 93.43% of the companies in the same industry.
The Return On Equity of BDTX (10.53%) is better than 93.25% of its industry peers.
BDTX has a better Return On Invested Capital (3.18%) than 90.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.43% | ||
| ROE | 10.53% | ||
| ROIC | 3.18% |
ROA(3y)-55.6%
ROA(5y)-47.58%
ROE(3y)-77.74%
ROE(5y)-63.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BDTX's Profit Margin of 20.00% is amongst the best of the industry. BDTX outperforms 94.18% of its industry peers.
BDTX has a better Operating Margin (8.57%) than 90.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.57% | ||
| PM (TTM) | 20% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for BDTX has been increased compared to 1 year ago.
The number of shares outstanding for BDTX has been increased compared to 5 years ago.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BDTX has an Altman-Z score of 1.59. This is a bad value and indicates that BDTX is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.59, BDTX is doing good in the industry, outperforming 66.42% of the companies in the same industry.
BDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 1.59 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BDTX has a Current Ratio of 8.65. This indicates that BDTX is financially healthy and has no problem in meeting its short term obligations.
BDTX's Current ratio of 8.65 is fine compared to the rest of the industry. BDTX outperforms 76.55% of its industry peers.
A Quick Ratio of 8.65 indicates that BDTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.65, BDTX is in the better half of the industry, outperforming 76.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.65 | ||
| Quick Ratio | 8.65 |
3. Growth
3.1 Past
BDTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 127.07%, which is quite impressive.
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 8.85% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y127.91%
EPS Next 2Y13.32%
EPS Next 3Y4.59%
EPS Next 5Y8.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.56, the valuation of BDTX can be described as reasonable.
Based on the Price/Earnings ratio, BDTX is valued cheaper than 97.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.45. BDTX is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for BDTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.56 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BDTX indicates a rather cheap valuation: BDTX is cheaper than 97.75% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.02 | ||
| EV/EBITDA | -6.11 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.08
PEG (5Y)N/A
EPS Next 2Y13.32%
EPS Next 3Y4.59%
5. Dividend
5.1 Amount
BDTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.8
-0.01 (-0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners78.76%
Inst Owner Change-1.11%
Ins Owners0.59%
Ins Owner Change0.47%
Market Cap216.37M
Revenue(TTM)N/A
Net Income(TTM)14.00M
Analysts87.14
Price Target9.18 (141.58%)
Short Float %10.95%
Short Ratio5.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2222.91%
Min EPS beat(2)24.48%
Max EPS beat(2)4421.34%
EPS beat(4)4
Avg EPS beat(4)1121.29%
Min EPS beat(4)12.77%
Max EPS beat(4)4421.34%
EPS beat(8)8
Avg EPS beat(8)569.11%
EPS beat(12)12
Avg EPS beat(12)381.81%
EPS beat(16)16
Avg EPS beat(16)289.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.16%
PT rev (3m)-16.28%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-0.67%
EPS NY rev (1m)-2.46%
EPS NY rev (3m)42.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.56 | ||
| Fwd PE | N/A | ||
| P/S | 3.09 | ||
| P/FCF | 12.02 | ||
| P/OCF | 12.02 | ||
| P/B | 1.64 | ||
| P/tB | 1.64 | ||
| EV/EBITDA | -6.11 |
EPS(TTM)0.36
EY9.47%
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)0.32
FCFY8.32%
OCF(TTM)0.32
OCFY8.32%
SpS1.23
BVpS2.32
TBVpS2.32
PEG (NY)0.08
PEG (5Y)N/A
Graham Number4.33
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.43% | ||
| ROE | 10.53% | ||
| ROCE | 4.03% | ||
| ROIC | 3.18% | ||
| ROICexc | 76.81% | ||
| ROICexgc | 76.81% | ||
| OM | 8.57% | ||
| PM (TTM) | 20% | ||
| GM | N/A | ||
| FCFM | 25.71% |
ROA(3y)-55.6%
ROA(5y)-47.58%
ROE(3y)-77.74%
ROE(5y)-63.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 283.91% | ||
| Profit Quality | 128.57% | ||
| Current Ratio | 8.65 | ||
| Quick Ratio | 8.65 | ||
| Altman-Z | 1.59 |
F-Score9
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.69%
Cap/Depr(5y)322.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)127.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.43%
EPS Next Y127.91%
EPS Next 2Y13.32%
EPS Next 3Y4.59%
EPS Next 5Y8.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y106.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.97%
EBIT Next 3Y3.46%
EBIT Next 5Y-2.01%
FCF growth 1Y124.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y124.72%
OCF growth 3YN/A
OCF growth 5YN/A
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you provide the ChartMill fundamental rating for BLACK DIAMOND THERAPEUTICS I?
ChartMill assigns a fundamental rating of 4 / 10 to BDTX.
Can you provide the valuation status for BLACK DIAMOND THERAPEUTICS I?
ChartMill assigns a valuation rating of 5 / 10 to BLACK DIAMOND THERAPEUTICS I (BDTX). This can be considered as Fairly Valued.
Can you provide the profitability details for BLACK DIAMOND THERAPEUTICS I?
BLACK DIAMOND THERAPEUTICS I (BDTX) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for BDTX stock?
The Price/Earnings (PE) ratio for BLACK DIAMOND THERAPEUTICS I (BDTX) is 10.56 and the Price/Book (PB) ratio is 1.64.
Can you provide the financial health for BDTX stock?
The financial health rating of BLACK DIAMOND THERAPEUTICS I (BDTX) is 7 / 10.